Background/Aims: The involvement of respiratory muscles is a major predicting factor for survival in amyotrophic lateral sclerosis (ALS). Recent studies show that noninvasive ventilation (NIV) can relieve symptoms of alveolar hypoventilation. However, factors predicting survival in ALS patients when treated with NIV need to be clarified. Methods: We conducted a retrospective study of 33 consecutive ALS patients receiving NIV. Ten patients had bulbar onset. We determined the median survivals from onset, diagnosis and initiation of NIV and factors predicting survival. Statistical analysis was performed using the Kaplan-Meier test and Cox proportional hazard models. Results: The median initial and maximal total uses of NIV were 10 and 14 h/24h. The overall median survival from ALS onset was 34.2 months and worsened with increasing age and bulbar onset of the disease. The median survival from initiation of NIV was 8.4 months and was significantly poorer in patients with advanced age or with airway mucus accumulation. Survival from initiation of NIV was not influenced by respiratory parameters or bulbar symptoms. Conclusion: Advanced age at diagnosis and airway mucus accumulation represent poorer prognostic factors of ALS patients treated with NIV. NIV is a helpful treatment of sleep-disordered breathing, including patients with bulbar involvement.

1.
Chio A, Mora G, Leone M, Mazzini L, Cocito D, Giordana MT, et al: Early symptom progression rate is related to ALS outcome: a prospective population-based study. Neurology 2002;59:99–103.
2.
Christensen PB, Hojer-Pedersen E, Jensen NB: Survival of patients with amyotrophic lateral sclerosis in 2 Danish counties. Neurology 1990;40:600–604.
3.
Lee JR, Annegers JF, Appel SH: Prognosis of amyotrophic lateral sclerosis and the effect of referral selection. J Neurol Sci 1995;132:207–215.
4.
Czaplinski A, Yen AA, Appel SH: Amyotrophic lateral sclerosis: early predictors of prolonged survival. J Neurol 2006;253:1428–1436.
5.
Eisen A, Schulzer M, MacNeil M, Pant B, Mak E: Duration of amyotrophic lateral sclerosis is age dependent. Muscle Nerve 1993;16:27–32.
6.
Magnus T, Beck M, Giess R, Puls I, Naumann M, Toyka KV: Disease progression in amyotrophic lateral sclerosis: predictors of survival. Muscle Nerve 2002;25:709–714.
7.
Norris F, Shepherd R, Denys E, U K, Mukai E, Elias L, et al: Onset, natural history and outcome in idiopathic adult motor neuron disease. J Neurol Sci 1993;118:48–55.
8.
Ringel SP, Murphy JR, Alderson MK, Bryan W, England JD, Miller RG, et al: The natural history of amyotrophic lateral sclerosis. Neurology 1993;43:1316–1322.
9.
Stambler N, Charatan M, Cedarbaum JM: Prognostic indicators of survival in ALS. ALS CNTF Treatment Study Group. Neurology 1998;50:66–72.
10.
Desport JC, Preux PM, Truong TC, Vallat JM, Sautereau D, Couratier P: Nutritional status is a prognostic factor for survival in ALS patients. Neurology 1999;53:1059–1063.
11.
Mazzini L, Corra T, Zaccala M, Mora G, Del Piano M, Galante M: Percutaneous endoscopic gastrostomy and enteral nutrition in amyotrophic lateral sclerosis. J Neurol 1995;242:695–698.
12.
Arnulf I, Similowski T, Salachas F, Garma L, Mehiri S, Attali V, et al: Sleep disorders and diaphragmatic function in patients with amyotrophic lateral sclerosis. Am J Respir Crit Care Med 2000;161:849–856.
13.
Aboussouan LS, Khan SU, Banerjee M, Arroliga AC, Mitsumoto H: Objective measures of the efficacy of noninvasive positive-pressure ventilation in amyotrophic lateral sclerosis. Muscle Nerve 2001;24:403–409.
14.
Bourke SC, Bullock RE, Williams TL, Shaw PJ, Gibson GJ: Noninvasive ventilation in ALS: indications and effect on quality of life. Neurology 2003;61:171–177.
15.
Kleopa KA, Sherman M, Neal B, Romano GJ, Heiman-Patterson T: Bipap improves survival and rate of pulmonary function decline in patients with ALS. J Neurol Sci 1999;164:82–88.
16.
Newsom-Davis IC, Lyall RA, Leigh PN, Moxham J, Goldstein LH: The effect of non-invasive positive pressure ventilation (NIPPV) on cognitive function in amyotrophic lateral sclerosis (ALS): a prospective study. J Neurol Neurosurg Psychiatry 2001;71:482–487.
17.
Pinto AC, Evangelista T, Carvalho M, Alves MA, Sales Luis ML: Respiratory assistance with a non-invasive ventilator (Bipap) in MND/ALS patients: survival rates in a controlled trial. J Neurol Sci 1995;129(suppl):19–26.
18.
Bourke SC, Tomlinson M, Williams TL, Bullock RE, Shaw PJ, Gibson GJ: Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial. Lancet Neurol 2006;5:140–147.
19.
Brooks BR: El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial ‘Clinical limits of amyotrophic lateral sclerosis’ workshop contributors. J Neurol Sci 1994;124 (suppl):96–107.
20.
Hillel AD, Miller RM, Yorkston K, McDonald E, Norris FH, Konikow N: Amyotrophic lateral sclerosis severity scale. Neuroepidemiology 1989;8:142–150.
21.
Aboussouan LS, Khan SU, Meeker DP, Stelmach K, Mitsumoto H: Effect of noninvasive positive-pressure ventilation on survival in amyotrophic lateral sclerosis. Ann Intern Med 1997;127:450–453.
22.
Jablecki CK, Berry C, Leach J: Survival prediction in amyotrophic lateral sclerosis. Muscle Nerve 1989;12:833–841.
23.
Lyall RA, Donaldson N, Fleming T, Wood C, Newsom-Davis I, Polkey MI, et al: A prospective study of quality of life in ALS patients treated with noninvasive ventilation. Neurology 2001;57:153–156.
24.
Louwerse ES, Visser CE, Bossuyt PM, Weverling GJ: Amyotrophic lateral sclerosis: mortality risk during the course of the disease and prognostic factors. The Netherlands ALS Consortium. J Neurol Sci 1997;152 (suppl 1):S10–S17.
25.
Lo Coco D, Marchese S, Pesco MC, La Bella V, Piccoli F, Lo Coco A: Noninvasive positive-pressure ventilation in ALS: predictors of tolerance and survival. Neurology 2006;67:761–765.
26.
Miller RG, Rosenberg JA, Gelinas DF, Mitsumoto H, Newman D, Sufit R, et al: Practice parameter: the care of the patient with amyotrophic lateral sclerosis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology: ALS Practice Parameters Task Force. Neurology 1999;52:1311–1323.
27.
Bach JR: Amyotrophic lateral sclerosis: prolongation of life by noninvasive respiratory AIDS. Chest 2002;122:92–98.
28.
Sancho J, Servera E, Diaz J, Marin J: Efficacy of mechanical insufflation-exsufflation in medically stable patients with amyotrophic lateral sclerosis. Chest 2004;125:1400–1405.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.